Articles |
From the Department of Pharmacology, School of Medicine, East Carolina University, Greenville, NC.
Abstract Vascular smooth muscle has been reported to contain the A1 subtype of adenosine receptors, but the existence of such receptor(s) in coronary smooth muscle has not been established. In the present study, the 3H-labeled A1-selective antagonist [3H]8-cyclopentyl-1,3-dipropylxanthine ([3H]DPCPX) was used to demonstrate the specific binding in porcine coronary artery smooth muscle membranes. The binding was saturable with a Bmax of 6.43±1.02 fmol/mg protein. Scatchard analysis of the binding data provided a single binding site with a Kd of 0.21±0.025 nmol/L. In the competition experiments, adenosine receptor agonists and antagonists showed the following order of potency (nmol/L): S-N6-(2-endo-norbornyl)adenosine (S-ENBA) 0.11=R(-)-N6-phenylisopropyladenosine 0.32>DPCPX 3.2=xanthine amine congener 2.4=N6-cyclopentyladenosine 2.67>5'-(N-ethylcarboxamido)-adenosine 7.35>>2-[p-(2-carboxyethyl)-phenethyl-amino]-5'-(N-ethylcarboxamido)-adenosine 1000>theophylline 83 000. This order of potency fits the criteria for the A1 adenosine receptor. S-ENBA, a highly selective A1 receptor agonist, was used to investigate the effect on isoproterenol-mediated vasorelaxation and cAMP accumulation. S-ENBA (0.1 to 10 nmol/L) dose-dependently shifted the isoproterenol-mediated (10-8 to 10-5 mol/L) vasorelaxation to the right in vascular rings. S-ENBA (10 nmol/L) inhibited the basal cAMP levels by 36% and attenuated the isoproterenol (10-5 mol/L)stimulated cAMP by 25% in the coronary rings. These inhibitory effects of S-ENBA on isoproterenol-mediated cAMP-accumulation and vasorelaxation were abolished by pertussis toxin (100 ng/mL, overnight) treatment of the arteries. Similarly, the effects of S-ENBA on isoproterenol-mediated responses were antagonized by DPCPX. This study provides the evidence suggesting the existence of A1 adenosine receptors linked to adenylyl cyclase in an inhibitory manner through pertussis toxinsensitive G proteins in the coronary artery.
Key Words: A1 adenosine receptor coronary artery adenosine receptor antagonist cAMP G proteins
This article has been cited by other articles:
![]() |
D. S. Ponnoth, M. S. Sanjani, C. Ledent, K. Roush, T. Krahn, and S. J. Mustafa Absence of adenosine-mediated aortic relaxation in A2A adenosine receptor knockout mice Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1655 - H1660. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Shen, S. P. Halenda, M. Sturek, and P. A. Wilden Novel Mitogenic Effect of Adenosine on Coronary Artery Smooth Muscle Cells: Role for the A1 Adenosine Receptor Circ. Res., May 13, 2005; 96(9): 982 - 990. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sato, K. Terata, H. Miura, K. Toyama, F. R. Loberiza Jr., O. A. Hatoum, T. Saito, I. Sakuma, and D. D. Gutterman Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1633 - H1640. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. E. Tawfik, J. Schnermann, P. J. Oldenburg, and S. J. Mustafa Role of A1 adenosine receptors in regulation of vascular tone Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1411 - H1416. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |